Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

This study has been completed.
Sponsor:
Collaborator:
Onyx Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01351623
First received: May 9, 2011
Last updated: January 27, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2016
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):